Inadequate response to targeted immunomodulators for rheumatoid arthritis may lead to significantly higher economic burden, including higher health care resource utilization. READ MORE

News

A recent study summarized the available evidence on adverse events associated with checkpoint inhibitors in patients with cancer and preexisting autoimmune disease.

READ MORE

Higher scores on a multi-biomarker disease activity system are associated with hospital infection, myocardial infarction, and coronary heart disease events in older patients with rheumatoid arthritis.

READ MORE

A myriad of factors including lack of guidelines, wealth of drug options, cost concerns, and varying efficacy make treatment decisions for rheumatoid arthritis a challenge.

READ MORE

A psoriasis drug is now approved to treat psoriatic arthrits in adults.

READ MORE

Research in Review

An analysis of biologics for rheumatoid arthritis showed tocilizumab monotherapy and tocilizumab plus methotrexate were superior to conventional drugs.

READ MORE

Patients with RA previously treated to a first-line TNF drug may experience a better outcome with a non-TNF biologic agent than with a second anti-TNF therapy.

READ MORE

The presence of two cellular biomarkers may help to identify patients with rheumatoid arthritis who will not benefit from rituximab. 

READ MORE

There may be little difference between treatment strategies that utilize musculoskeletal ultrasound or disease activity in rheumatoid arthritis measurements.

READ MORE